SNDX Q4 2022 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$42M

Net Income

-$39M

EPS (Diluted)

$-0.62

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$497M

Total Liabilities

$30M

Stockholders' Equity

$467M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$127M	-100.0%
Gross Profit	$0	$126M	-100.0%
Operating Income	-$42M	$96M	-143.9%
Net Income	-$39M	$96M	-140.7%